Abstract
Proper activation of phosphoinositide 3-kinase-Akt pathway is critical for the prevention of tumorigenesis. Recent data have characterized a negative feedback loop, wherein mammalian target of rapamycin (mTOR) blocks additional activation of the Akt/mTOR pathway through inhibition insulin receptor substrate 1 (IRS-1) function. However, the potential of IRS-1 inhibition during rapamycin treatment has not been examined. Herein, we show that IRS-1 antisense oligonucleotide and rapamycin synergistically antagonize the activation of mTOR in vivo and induced tumor suppression, through inhibition of proliferation and induction of apoptosis, in prostate cancer cell xenografts. These data demonstrate that the addition of agents that blocks IRS-1 potentiate the effect of mTOR inhibition in the growth of prostate cancer cell xenografts.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adaptor Proteins, Signal Transducing / drug effects*
-
Adaptor Proteins, Signal Transducing / metabolism
-
Animals
-
Antibiotics, Antineoplastic / pharmacology*
-
Apoptosis / drug effects
-
Blotting, Western
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Enzyme Activation / drug effects
-
Enzyme Activation / physiology
-
Humans
-
Insulin Receptor Substrate Proteins
-
Male
-
Mice
-
Mice, SCID
-
Phosphorylation / drug effects
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / metabolism
-
Protein Kinases / drug effects
-
Protein Kinases / metabolism
-
Signal Transduction / drug effects*
-
Sirolimus / pharmacology*
-
TOR Serine-Threonine Kinases
-
Xenograft Model Antitumor Assays
Substances
-
Adaptor Proteins, Signal Transducing
-
Antibiotics, Antineoplastic
-
IRS1 protein, human
-
Insulin Receptor Substrate Proteins
-
Irs1 protein, mouse
-
Protein Kinases
-
MTOR protein, human
-
mTOR protein, mouse
-
TOR Serine-Threonine Kinases
-
Sirolimus